Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy
Authors:
- Linda GalassoLGLinda Galasso
- Federica VitaleFVFederica Vitale
- Gabriele GiansantiGGGabriele Giansanti
- Giorgio EspostoGEGiorgio Esposto
- Raffaele BorrielloRBRaffaele Borriello
- Irene MigniniIMIrene Mignini
- Alberto NicolettiANAlberto Nicoletti
- Lorenzo Zileri Dal VermeLVLorenzo Zileri Dal Verme
- Antonio GasbarriniAntonio Gasbarrini
- Maria Elena AinoraMAMaria Elena Ainora
- Maria Assunta ZoccoMZMaria Assunta Zocco
Open Access
- 13 August 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7814
Abstract
Pancreatic neuroendocrine tumors (pNETs) are rare malignancies, accounting for 1–2% of pancreatic cancers, with an incidence of ≤1 case per 100,000 individuals annually. Originating from pancreatic endocrine cells, pNETs display significant clinical and biological heterogeneity. Traditional classification based on proliferative grading does not fully capture the complex mechanisms involved, such as oxidative stress, mitochondrial dysfunction, and tumor-associated macrophage infiltration. Recent advances in molecular profiling have revealed key oncogenic drivers, including MEN1 (menin 1), DAXX (death domain–associated protein), ATRX (alpha thalassemia/mental retardation syndrome X-linked), CDKN1B (cyclin-dependent kinase inhibitor 1B) mutations, chromatin remodeling defects, and dysregulation of the mTOR pathway. Somatostatin receptors, particularly SSTR2, play a central role in tumor biology and serve as important prognostic markers, enabling the use of advanced diagnostic imaging (e.g., Gallium-68 DOTATATE PET/CT) and targeted therapies like somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Established biomarkers such as Chromogranin A and the Ki-67 proliferation index remain vital for diagnosis and prognosis, while emerging markers, like circulating tumor DNA and microRNAs, show promise for enhancing disease monitoring and diagnostic accuracy. This review summarizes the molecular landscape of pNETs and highlights genomic, transcriptomic, proteomic, and epigenomic factors that support the identification of novel diagnostic, prognostic, and therapeutic biomarkers, ultimately advancing personalized treatment strategies.Keywords
Funding Information
- Fondazione Roma (FRCEMAD 21-25)
This publication has 140 references indexed in Scilit:
- Characterization of the Pancreatic Neuroendocrine Neoplasm Immune MicroenvironmentCancer Medicine, 2025
- New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivoCancer Immunology, Immunotherapy, 2024
- Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trialsCancer, 2021
- Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safetyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATEEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- The endocrine role for chromogranin A: A prohormone for peptides with regulatory propertiesCellular and Molecular Life Sciences, 2007
- Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targetingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligandsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001